The Age-Related Eye Disease Study 2 (AREDS2) primary analysis did not show that adding lutein and zeaxanthin reduced progression to late age-related macular degeneration (AMD). Secondary and long-term findings point to a narrower use: people who already have intermediate AMD or late AMD in one eye may benefit from a clinician-selected formula, while the trial says nothing about relieving ordinary screen-related discomfort in healthy eyes.

This distinction matters because supplement marketing often detaches a result from the population that produced it. AREDS2 was a disease-progression trial in people at high risk, not a prevention trial in healthy adults and not a study of dry or tired eyes after screen use.

Sudden vision changes need prompt assessment

Sudden loss of vision requires emergency assessment through the local health system. The US National Eye Institute identifies wavy or crooked straight lines and new blurry or blank areas in central vision as signs of late AMD, and says people who see wavy lines should contact an eye doctor immediately. A supplement should not delay that assessment.

Children, pregnant or breastfeeding people, people with chronic conditions, and anyone taking regular medicines should discuss an eye supplement with a clinician. The cited AREDS2 evidence does not establish separate benefits or risks for all of these groups, and supplement ingredients can differ between products and countries.

The main AREDS2 comparison fell short of the statistical threshold

AREDS2 enrolled 4,203 adults aged 50 to 85 who were at high risk of progressing to late AMD. About two-thirds had large deposits known as drusen in both eyes, while about one-third had late AMD in one eye. Those entry criteria exclude healthy eyes and most people buying supplements solely because they use digital screens.

In the trial's primary analysis, adding lutein and zeaxanthin produced a hazard ratio of 0.90 for progression to late AMD, with a P value of 0.12. The result did not meet the usual threshold for statistical significance. It therefore does not support a claim that the addition reduced progression for the full study group.

Chart comparing the nonsignificant AREDS2 primary result with a secondary low-dietary-intake subgroup (illustrative image)

The larger reduction came from a secondary subgroup

A secondary AREDS2 analysis reported a hazard ratio of 0.74 among participants in the lowest fifth of dietary lutein and zeaxanthin intake. That corresponds to a 26 percent relative reduction within that subgroup, not a 26 percent reduction for everyone taking lutein.

Subgroup findings can identify a plausible difference between participants, but they carry more uncertainty than a prespecified primary comparison. The analysis also remained confined to the original high-risk AREDS2 population. It cannot be extended to healthy eyes or treated as evidence that a supplement prevents AMD.

A 10-year follow-up reported a hazard ratio of 0.91 for progression to late AMD among participants assigned lutein and zeaxanthin rather than no lutein and zeaxanthin. The same report found a higher lung-cancer risk among participants assigned beta carotene, most of whom were former smokers, while it did not detect an increase with lutein and zeaxanthin. This safety difference is part of the reason later AREDS formulations replaced beta carotene; it is not evidence of a general eye-health effect.

The formula does not prevent AMD in healthy eyes

The US National Eye Institute says AREDS and AREDS2 supplements may slow progression from intermediate to late AMD and may help people who have late AMD in one eye. The institute also says the supplements do not prevent AMD and do not stop early AMD from progressing to intermediate AMD.

That boundary rules out a population-wide recommendation. A person with an AMD diagnosis needs an eye care professional to determine the disease stage and whether an AREDS2-type formula fits that diagnosis. People without AMD should not infer a preventive benefit from a trial that did not enroll them for that purpose.

Screen discomfort is not the outcome AREDS2 measured

AREDS2 measured progression to late AMD. It did not test whether lutein relieves dryness, irritation, blurred focus or fatigue associated with long periods of near work.

A 2023 Cochrane review of 17 randomized trials found that blue-light filtering lenses may not reduce short-term eye strain during computer use compared with lenses that do not filter blue light. The review found little or no effect on best-corrected visual acuity and no randomized-trial evidence for macular-health outcomes; it could not determine longer-term retinal effects.

A computer user takes a distance-viewing break while a bottle of eye supplements sits unopened (illustrative image)

Those measures address screen-use conditions rather than AMD. Persistent discomfort, recurrent blurred vision or a change in sight needs clinical assessment because symptoms alone cannot identify the cause.

How to read a lutein claim

First check whether the advertised population matches the research population. A statement based on AREDS2 should identify people with intermediate AMD or late AMD in one eye, rather than describing all adults, screen users or people with healthy eyes.

Next separate the primary result from subgroup and follow-up findings. The primary comparison for adding lutein and zeaxanthin did not meet the statistical threshold, while the larger relative reduction came from participants with the lowest dietary intake. Marketing that presents the subgroup figure as a universal effect leaves out that distinction.

Finally, check the full ingredient list with a clinician instead of treating the word “lutein” as proof that a product matches the studied formula. Supplement regulation, labeling and availability vary by country, and APPI News did not verify individual products across every market.

Frequently asked questions

Does AREDS2 show that everyone should take lutein?
No. The trial enrolled people already at high risk of late AMD. Its findings do not establish a benefit for healthy eyes or for routine screen discomfort.

Did lutein and zeaxanthin reduce AMD progression by 25 percent?
Not in the trial's primary analysis. A reduction of about that size appeared in a secondary analysis of participants in the lowest fifth of dietary lutein and zeaxanthin intake.

Can an AREDS2 supplement prevent AMD?
The US National Eye Institute says these supplements do not prevent AMD and do not help stop early AMD from progressing to the intermediate stage.

Does screen blue light mean a lutein supplement is needed?
AREDS2 did not study screen-related eye strain. A 2023 Cochrane review found that blue-light filtering lenses may not reduce short-term eye strain during computer use, and it found no randomized-trial evidence on macular-health outcomes.

Who should discuss an AREDS2 formula with an eye care professional?
People diagnosed with intermediate AMD or late AMD in one eye are the groups identified by the US National Eye Institute. The clinician should confirm the disease stage and review the full formulation, health history and regular medicines.